Home » Stocks » RGLS

Regulus Therapeutics Inc. (RGLS)

Stock Price: $0.954 USD 0.076 (8.60%)
Updated Jun 21, 2021 12:51 PM EDT - Market open
Market Cap 65.84M
Revenue (ttm) 10.00M
Net Income (ttm) -15.81M
Shares Out 71.29M
EPS (ttm) -0.34
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day June 21
Last Price $0.954
Previous Close $0.879
Change ($) 0.076
Change (%) 8.60%
Day's Open 0.910
Day's Range 0.903 - 0.980
Day's Volume 4,855,773
52-Week Range 0.422 - 2.320

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

SAN DIEGO, June 21, 2021 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the ...

6 hours ago - PRNewsWire

Which penny stocks are worth buying next month? Check these 7 out for your watchlist The post 7 Hot Penny Stocks to Watch That Are Trending Right Now appeared first on Penny Stocks to Buy, Picks, News a...

Other stocks mentioned: AMRN, COCP, EEIQ, LKCO, METX, NBY
17 hours ago - PennyStocks

Investors need to pay close attention to Regulus Therapeutics (RGLS) stock based on the movements in the options market lately.

1 week ago - Zacks Investment Research

These penny stocks are expecting to release key information this month. The post Biotech Penny Stocks To Watch For June 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | PennySto...

Other stocks mentioned: APTO, FBIO, MBIO
2 weeks ago - PennyStocks

Regulus Therapeutics Inc (NASDAQ: RGLS) has announced an incremental update from the first cohort of patients from its ongoing Phase 1b trial evaluating RGLS4326 in Autosomal Dominant Polycystic Kidney ...

1 month ago - Benzinga

SAN DIEGO, May 21, 2021 /PRNewswire/ --  Regulus Therapeutics Inc.  (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the ...

1 month ago - PRNewsWire

SAN DIEGO, May 14, 2021 /PRNewswire/ --  Regulus Therapeutics Inc.  (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs ("Reg...

1 month ago - PRNewsWire

Regulus (RGLS) delivered earnings and revenue surprises of 11.11% and -100.00%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

SAN DIEGO, May 13, 2021 /PRNewswire/ --  Regulus Therapeutics Inc.  (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the ...

1 month ago - PRNewsWire

SAN DIEGO, May 6, 2021 /PRNewswire/ --  Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "C...

1 month ago - PRNewsWire

Regulus (RGLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago - Zacks Investment Research

Regulus Therapeutics Inc (NASDAQ: RGLS) has announced top-line results from the first cohort of patients (n=9) with Autosomal Dominant Polycystic Kidney Disease (ADPKD) in its ongoing Phase 1b trial of ...

1 month ago - Benzinga

LA JOLLA, Calif., May 3, 2021 /PRNewswire/ --  Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs ...

1 month ago - PRNewsWire

LA JOLLA, Calif., April 15, 2021 /PRNewswire/ -- Regulus Therapeutics Inc.  (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRN...

2 months ago - PRNewsWire

LA JOLLA, Calif., April 7, 2021 /PRNewswire/ -- Regulus Therapeutics Inc.  (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNA...

2 months ago - PRNewsWire

Investors seem to believe something may be cooking with RGLS stock right now, given the outsized move we've seen today on a lack of news. The post RGLS Stock: 7 Things to Know About Red-Hot Regulus Ther...

Other stocks mentioned: SNY
3 months ago - InvestorPlace

LA JOLLA, Calif., March 9, 2021 /PRNewswire/ --  Regulus Therapeutics Inc.  (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRN...

3 months ago - PRNewsWire

LA JOLLA, Calif., March 5, 2021 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs...

3 months ago - PRNewsWire

Regulus (RGLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 months ago - Zacks Investment Research

LA JOLLA, Calif., Feb. 10, 2021 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs...

4 months ago - PRNewsWire

LA JOLLA, Calif., Jan. 27, 2021 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs...

4 months ago - PRNewsWire

LA JOLLA, Calif., Jan. 5, 2021 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs ...

5 months ago - PRNewsWire

Billionaire investor Steven Cohen (Trades, Portfolio) disclosed earlier this week his firm, Point72 Asset Management, established a 14.37% stake in Regulus Therapeutics Inc. (NASDAQ:RGLS) and a 7.96% po...

Other stocks mentioned: ALNA
6 months ago - GuruFocus

Investors need to pay close attention to Regulus Therapeutics (RGLS) stock based on the movements in the options market lately.

6 months ago - Zacks Investment Research

LA JOLLA, Calif., Dec. 8, 2020 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs,...

6 months ago - PRNewsWire

MINNEAPOLIS, Dec. 2, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) and Regulus Therapeutics (NASDAQ: RGLS) announced a collaboration to support Regulus with biomarker analysis for the clini...

Other stocks mentioned: TECH
6 months ago - PRNewsWire

Regulus (RGLS) delivered earnings and revenue surprises of 80.00% and 880.39%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

7 months ago - Zacks Investment Research

LA JOLLA, Calif., Nov. 5, 2020 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs ...

7 months ago - PRNewsWire

Regulus (RGLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

7 months ago - Zacks Investment Research

LA JOLLA, Calif., Nov. 2, 2020 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs,...

7 months ago - PRNewsWire

LA JOLLA, Calif., Oct. 15, 2020 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs...

8 months ago - PRNewsWire

LA JOLLA, Calif., Oct. 13, 2020 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS) (the "Company" or "Regulus"), a biopharmaceutical company focused on the discovery and development of innovative ...

8 months ago - PRNewsWire

LA JOLLA, Calif., Sept. 11, 2020 /PRNewswire/ -- Regulus Therapeutics Inc.

9 months ago - PRNewsWire

LA JOLLA, Calif., Sept. 3, 2020 /PRNewswire/ -- Regulus Therapeutics Inc.

9 months ago - PRNewsWire

LA JOLLA, Calif., Aug. 31, 2020 /PRNewswire/ -- Regulus Therapeutics Inc.

9 months ago - PRNewsWire

Regulus (RGLS) delivered earnings and revenue surprises of -9.52% and -100.00%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

10 months ago - Zacks Investment Research

LA JOLLA, Calif., Aug. 13, 2020 /PRNewswire/ -- Regulus Therapeutics Inc.

10 months ago - PRNewsWire

Regulus (RGLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

10 months ago - Zacks Investment Research

LA JOLLA, Calif., Aug. 6, 2020 /PRNewswire/ -- Regulus Therapeutics Inc.

10 months ago - PRNewsWire

LA JOLLA, Calif., Aug. 3, 2020 /PRNewswire/ -- Regulus Therapeutics Inc.

10 months ago - PRNewsWire

LA JOLLA, Calif., July 29, 2020 /PRNewswire/ -- Regulus Therapeutics Inc.

10 months ago - PRNewsWire

LA JOLLA, Calif., July 22, 2020 /PRNewswire/ -- Regulus Therapeutics Inc.

10 months ago - PRNewsWire

LA JOLLA, Calif., May 14, 2020 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs ...

1 year ago - PRNewsWire

Regulus (RGLS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 year ago - Zacks Investment Research

Regulus (RGLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 year ago - Zacks Investment Research

Regulus (RGLS) delivered earnings and revenue surprises of 10.34% and -10.00%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

Regulus (RGLS) delivered earnings and revenue surprises of 50.00% and -99.28%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

Regulus (RGLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 year ago - Zacks Investment Research

Regulus (RGLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 years ago - Zacks Investment Research

About RGLS

Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that target microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS4326, an anti-miR targeting miR-17, which is in Phase 1 development for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of p... [Read more...]

Industry
Biotechnology
IPO Date
Oct 4, 2012
CEO
Joseph Hagan
Employees
23
Stock Exchange
NASDAQ
Ticker Symbol
RGLS
Full Company Profile

Financial Performance

In 2020, RGLS's revenue was $10.01 million, an increase of 46.46% compared to the previous year's $6.83 million. Losses were -$15.73 million, -15.39% less than in 2019.

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for RGLS stock is "Hold." The 12-month stock price forecast is 1.17, which is an increase of 22.59% from the latest price.

Price Target
$1.17
(22.59% upside)
Analyst Consensus: Hold